- Agreement signed on February 3, 2026, for HiSAP lead compounds.
- Asahi Kasei Pharma acquires exclusive global rights to research, develop, manufacture, and commercialize the compounds.
- Alchemedicine to receive up to ¥41.3 billion in payments and royalties.
- Focus on developing treatments for autoimmune diseases.
Agreement Overview
Alchemedicine Inc. and Asahi Kasei Pharma Corporation have entered into an exclusive license agreement concerning HiSAP lead compounds. The agreement was signed on February 3, 2026, granting Asahi Kasei Pharma global rights to research, develop, manufacture, and commercialize these compounds.
Financial Terms
Under the terms of the agreement, Alchemedicine will receive an upfront payment along with development, regulatory, and sales milestones, totaling up to ¥41.3 billion. Additionally, Alchemedicine will earn royalties based on future product sales.
Research and Development Focus
The partnership aims to leverage Alchemedicine’s HiSAP medicinal chemistry platform and Asahi Kasei Pharma’s R&D expertise. The focus will be on developing new therapeutic options for autoimmune diseases, utilizing the mechanism of the HiSAP compounds.
Future Plans
Asahi Kasei Pharma will evaluate potential therapeutic indications for the compounds, with an emphasis on autoimmune diseases. Both companies are committed to creating innovative medicines to address unmet medical needs in severe and refractory diseases.
